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Abstract: 
Indinavir (Crivaxan®) is a potent inhibitor of the HIV (human immunodeficiency virus) protease. This enzyme has an important role in viral 
replication and is considered to be very attractive target for new antiretroviral drugs. However, it becomes less effective due to highly resistant 
new viral strains of HIV, which have multiple mutations in their proteases. For this reason, we used a lead expansion method to create a new set 
of compounds with a new mode of action to protease binding site. 1300 compounds chemically diverse from the initial hit were generated and 
screened to determine their ability to interact with protease and establish their QSAR properties. Further computational analyses revealed one 
unique compound with different protease binding ability from the initial hit and its role for possible new class of protease inhibitors is discussed 
in this report.  
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Background : 
The HIV-1 (human immunodeficiency virus type 1) protease is a C2 
symmetric and an aspartic acid homodimeric enzyme, where aspartate 
25 plays a pivotal role in binding the substrate [1]. The HIV-1 protease 
does not have a homologue in mammalian cells and has a function to 
cleave the Gag-Pol polyprotein precursor into shorter pieces to create 
the active protein components for viral packaging and maturation. This 
proteolysis occurs late in the viral life cycle and is essential for viral 
infectivity [2]. The protease active site is located in the buried area 
(tunnel), where the two subunits meet each other. Highly active 
antiretroviral therapy (HAART), using protease inhibitors (PI), is 
commonly used in management of HIV infection. These inhibitors are 
able to irreversibly bind the HIV-1 protease to block its function. 
Among these compounds, Indinavir (Crixivan, MK-639, or IDV) [3, 4] 
is a potent and selective protease inhibitor that had approval for AIDS 
therapy. But genotypic analyses of the viral populations during the 
course of protease inhibitor therapy had shown various mutations that 
can occur in as many as 20 amino acids within the protease gene [5, 
6]. 13.7 % of IDV failure were identified for 1021 new viral genotypes 
from HIV patients [7]. In case of HIV-1 subtype C (African strain), it 
had been shown that the most common primary mutation observed in 
PI treated patients was L90M [8], a main course in multi-PI resistance 
establishment  [9]. Even naturally occurring polymorphism, such as 
L89M and I93L, located in the hydrophobic core of the enzyme would 
possibly change the shape of the substrate-binding cleft and diminish 
the potency of IDV [10]. Only flexibility of the newly synthesized 
compounds seems to overcome this effect. Here, we describe the 
designing scheme for possible HIV-1 protease inhibitors using a lead 
expansion protocol with a pharmacophoric-shape similarity scoring 
function. 
 
Methodology: 
HIV-1 subtype C protease and Indinavir structures: 
The three dimensional structure of the HIV-1 protease - IDV complex 
(PDB code: 2R5P) was retrieved from Protein Data Bank at 2.3 Å 
RMSD resolution [10]. The VADAR (volume, area, dihedral angle 
reporter) server [11], which is an improved version of the 
PROCHECK software, was used for stereochemical validation of 
HIV-1 protease. Altogether, 95 % of all residues were in φ-ψ core 
areas. Indinavir was obtained from PubChem database (CID: 
5362440). IDV initial refinement was performed by means of the 
MarvinSketch program provided by ChemAxon [12]. 
 
Protease active site detection: 
Protein binding surfaces could have very complicated and irregular 
structures. Atoms could form pockets, cavities and tunnels. Solvent 
molecules can get into these tunnels from outer environment and move 
through them. Buried shape and volume of such tunnels vary in time 
due to protein dynamics and kinetics. Here, we analyzed buried 
tunnels of the protease using the CAVER module, to identify certain 
atomic positions of hidden binding moieties [13]. Dijkstra’s algorithm 
was implemented in searching process and started from source node 
(starting point), which is located deeply in the protein pocket. Before 
the search procedure, 136 water molecules, chloride and sodium ions 
were removed from IDV-bound protease (liganded holo-structure) 
protein database file. All calculations were performed on 32612 grid 
points. Catalytic tunnel (key interaction site) was detected in the 
protease structure (Figure 2(A)). The tunnel coordinates to specify the 
starting point in x, y and z axis are 2.5, 6.5, -7.5 respectively. These 
coordinates were taken from the AutoDock manual [14].IDV  
 
Compound library generation:  
Pharmacophoric - shape similarity scoring function was used for 
compound library generation. This is build-in function integrated in 
the Muse™ molecular design workflow to accelerate the identification 
and optimization of lead candidates. This function seeks molecules 
that have fairly different structures but similar 3D pharmacophores and 
shapes. It is appropriate for lead expansion – exploration around an 
initial hit. Indinavir compound was used as a reference molecule and 
all similarities were measured with respect to it. The reference 
structure was also used as the initial population for invention. In our 
case a default set of compounds was used if no any other structures 
were given. Such generation of multiple compounds with similar 
shape but different 3D structure organization would provide more 
interesting results in the invention and library screening afterwards. 
For lead expansion method we did not specified any seed structures 
and preserved cores. 99 undesirable and 35 questionable substructures 
were excluded from to be present in invented structures. Structural 
ranking was done by means of the Pareto-Borda method to maximize 
pharmacophoric-shape similarity in preferential shape similarity 
specified range (from 0.35 to 0.50 score units).  
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Figure 1: Chemical structure of IDV and its ‘derivate’- novel hit (N'-cyano-N-{3-[(1S, 2S)-1,2-diamino-2-(4-oxo-3, 4-dihydroquinazolin-7-
yl)ethyl]-5-[(2R)-oxolan-2-yl]pyridin-2-yl}benzenecarboximidamide) 
 
 
Figure 2: (A) HIV protease catalytic tunnel (binding site) was predicted by PyMol CAVER module. IDV (B) and novel hit (C) interactions with 
the HIV-1 protease are shown. H-bonds are depicted as dashed lines. IDV – protease complex was analyzed as a crystal structure. 3D alignment 
and ‘fuzzy’ model (D) of the hit ‘native’ conformation (gray) together with its ‘functional’ conformation (yellow) at 2.0 Å RMSD. The shown 
potential pharmacophore points are color-coded as follows: lipophilic areas are green, H-bond donors and acceptors are colored in blue and red 
respectively. 
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ADME/Tox studies 
Available decision tree algorithms such as: Benigni-Rossa rulebase, 
Verhaar scheme, Cramer rules and START (structural alerts for 
reactivity in toxtree) biodegradability were used for the analysis. 
Benigni-Rossa rule base predicts the possibility of carcinogenicity and 
mutagenecity by discriminant analysis and structural rules [15]. 
START biodegradability estimates biodegradation potential of the 
chemical compound based on structural alerts compiled from the 
Canadian Environmental Protection Agency. 
 
Protein-ligand docking 
The Molegro Virtual Docker [16] and the AutoDock software were 
implemented to analyze ligand interactions with the HIV-1 protease 
binding site. The Molegro Virtual Docker and the AutoDock combine 
a rapid energy evaluation through pre-calculated grids of affinity 
potentials with a variety of search algorithms to find appropriate 
binding positions. In Molegro Virtual Docker docking experiment we 
used MolDock scoring function, which is based on a piecewise linear 
potential and a re-ranking procedure was applied to the highest ranked 
poses to increase docking accuracy. Affinity grid resolution was set to 
0.3 Å. Ligand evaluations were based on internal energy of binding, 
internal H-bonds formation, Sp2-Sp2 (trigonal planar electron domain 
geometry) torsion angles.  Binding site was previously detected by 
CAVER module and further measured for cavity volume (282.1 Å
3), 
surface (681.0 Å
2) and radius (15.0 Å). Customized search algorithm 
was set to MolDock SE (simplex evolution). Number of runs was 10. 
Parameter settings were set to 1500 iterations, 50 population sizes, 
100.0 kcal/mol of energy threshold for pose generation, 300 simplex 
evolution steps and 1.0 neighbor distance factor. All dockings were 
performed at 1.0 Å RMSD threshold. For preparing the AutoDock 
docking parameter file we used default settings (genetic algorithm 
parameters:  population size = 150, number of energy evaluations = 
2500000, rate of gene mutation = 0.02, rate of crossover = 0.8, 
maximum number of generations = 27000, number of GA runs = 10, 
initial dihedrals were randomly specified, elitism value was set to 1). 
By default, clustering of docked results was done at 0.5 Å RMSD. 
Prior to docking, total Kollman and Gasteiger charges were added to 
the protein and the ligand.  
 
LIQUID-fuzzy pharmacophore models 
The PyMol LIQUID module was utilized to create a pharmacophore 
‘fuzzy’ model. At the first model computation LIQUID used standard 
cluster radii to calculate cluster sizes at 4.0 Å RMSD for lipophilic 
areas and 1.9 Å RMSD for H-bond donors and acceptors [17]. In our 
experiment we set up default cluster radius (2.0 Å) for each potential 
pharmacophore point type (Figure 2(D)).  
Discussion:  
Genetic algorithm produced 1300 compounds (70 generations) of 
diverse chemical structure. 500 of top molecules were selected 
according to their shape similarity (0.7-0.9 functional scores). These 
molecules, which had pharmacophoric score less than 0.8 were 
excluded from the list. 227 out of 500 compounds satisfied all that 
criteria and were tested for Lipinski’s Rule of Five using the 
LigandScout pharmacophore software [18]. Only one compound 
(novel hit) did not have rule violations, in contrast to IDV, which had 
one violation of Lipinski’s rule. A useful parameter, such as 
topological polar surface area (TPSA), was defined for these two 
molecules as the surface sum over all polar atoms to evaluate 
parameters for the prediction of cell permeability and drug transport 
properties (Table 1 in supplementary material). This parameter shows 
good drug transport, even in ability to penetrate the blood-brain 
barrier. In this case TPSA should not exceed 600 Å
2 threshold. The 
novel hit was analyzed for Cramer rules, carcinogenicity and 
biodegradability. It also showed a strong affinity (in comparison with 
reference molecule) to the HIV-1 protease binding site. Docking 
results revealed the interaction modes for this compound with the 
HIV-1 protease. Novel hit adopts IDV binding mode (Asp 25, 29 and 
Gly 27) and also has the additional interacting residues (Gly 49-Ile 50, 
Asp 29-Ala 28, Asp 30). Moreover, it exceeds IDV in H-bond 
formations (10 instead of 9). New compound’s nitrile group is creating 
H-bonds with donor nitrogen of Gly 49 - Ile 50 amide group (Figure 
2(B, C)).  
 
Probably this acceptor nitrile group along with the tetrahydropyridine 
ring might have some influence on the ligand conformational shift 
with subsequent change in binding affinity mode. In both docking 
cases, the catalytic function of the Asp 25 residues is completely 
blocked. Subsequently, we performed the AutoDock experiments to 
validate the above data and revealed reduction in hydrogen bonds 
formation presumably due to differences in affinity grid resolution of 
Molegro Virtual Docker and AutoDock (0.3 vs 0.375 Å). However, 
consistent with previous observation, all crucial amino acids obtained 
from Molegro docking experiments are also present in the AutoDock 
docking profiles (Figure 3(A, B)).The IDV spatial conformation 
recruits less docking energy (-15.1 kcal/mol) in comparison to novel 
hit and forms H-bonds with amino acid residues of chain B. In this 
orientation, the amide nitrogen donor together with carboxyl group 
(hydroxyl moiety) of the Asp 29 residue, the Asp 25 carboxyl group 
(hydroxyl moiety) and the Gly 27 amide oxygen acceptor make 
hydrogen bonds with two hydroxyl functional groups and one amide 
nitrogen donor of the ligand molecule.  
 
 
Figure 3: (A) Indinavir and (B) novel hit docking profiles calculated by AutoDock software. Both ligands are gray. HIV protease chain A and B 
amino acids are painted in green and magenta respectively. The hydrogen bonds are shown for each of both molecules; see text for details. Bioinformation   open access 
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Although, novel hit conformation interacts with both chains of the 
HIV protease but its global minimum in docked energy (-13.8 
kcal/mol) with the protease binding site is more than that of IDV, 
resulting in decrease of binding affinity and intermolecular force 
between the ligand and its receptor. The Asp 29, Ile 50 amide nitrogen 
donors form H-bonds with N
1 of the tetrahydropyrimidine ring and 
nitrogen acceptor of the aminoformonitrile residue. Carbonyl and 
hydroxyl moieties of both Asp 25 carboxyl groups are interacting with 
amine functional donor groups of novel hit. Asp 25, Asp 29, Gly 27 
residues are located in the ‘eye’ areas, whereas Ile 50 residue is 
localized in the ‘flap’ region. The ‘flap’ region of the protease plays an 
important role in the enzyme “opening” and ligand binding to the 
‘flap’ β-hairpins could block “opening” process.Finally, we measured 
the hydrogen bond length by measuring the distance between the 
donor and acceptor atoms. Usually, longest H-bond length is about 3.5 
Å. Anything longer of this parameter would be considered a pure 
dipole-dipole interaction. It is well established that hydrogen bonds 
have a typical length around 2.5 Å. In our case, all H-bond distances 
were in the range from 1.71 to 2.11 Å.  Interestingly, one bond in IDV 
and two bonds in the hit molecule were detected as ultra-short 
hydrogen bonds with donor and acceptor distances of less than 2.0 Å. 
This observation supports further that identified the novel hit 
compound should have a tendency to form strong hydrogen bonds to 
the protease catalytic center.One drawback to IDV and novel hit is 
that, they both have a heterocyclic rings with complex substituents. 
Those features are responsible for the third class of toxicity (highly 
toxic). Both molecules belong to the second class of biodegradability, 
which means no alerts for notifying an easily degradable chemical 
were found and there was one alert notifying a persistent chemical the 
compound under investigation is declared as “persistent chemical”.  
 
Conclusion:  
In the present study, we generated library of diverse chemical 
compounds on the bases of Indinavir and screened them for possible 
anti-protease activity. However, mutagenic efficiency of HIV is very 
high in generating new viral strains and could be bypassed by creating 
drugs with different binding properties and strong affinity to the target 
protein. The results are shown in this report, indicate that at least one 
compound has binding residues different from the initial hit, with 
improved affinity to the protease as well as its QSAR properties. 
Further studies on this compound will provide useful information 
towards the rational design of HIV-1 protease inhibitors and their 
effectiveness. 
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Supplementary material 
 
Table 1: Comparative characteristics of IDV and novel hit  
Molecular properties  IDV  Novel hit 
Atoms 92  63 
MW (≤ 500)  613.8↑ 494.6 
TPSA (Å
2) 118  181 
cLogP (≤ 5)  2.9  2.4 
HBD (≤ 5)  4  4 
HBA (≤ 10)  7  6 
NI
1  0 0 
PI
2  2 3 
Docking results    
MolDock Score  -  -185.7 
Rerank Score  -  -148.5 
Docking Score  -  -191.6 
H-bond energy  -  -12.8 
Flexible torsions 
Energy Minimum              
- 
-15.1 
8 
-13.8 
ADME/Tox    
Cramer rules  Class 3  Class 3 
Biodegradability  Class 2  Class 2 
Carcinogenicity no no 
1negative ionizable groups; 
2positive ionizable groups 
 